StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3076% above fair value
$266.17−4.39 (-1.62%)

Close on Nov 3, 2026Market cap $641.44BP/E 40.4Yield 1.93%

Johnson & Johnson SPRAVATO (esketamine) by Quarter

SPRAVATO (esketamine) — Worldwide operational (constant-currency) growth YoY (%) (%)

QuarterlyAnnual

Johnson & Johnson SPRAVATO (esketamine): 36.0% in Q3 2026, down 24.8 pts from a year earlier. That is the lowest of the 15 quarters on record here.

Latest, Q3 2026
36.0%
Period ended Sep 30, 2026
Change on a year earlier
-24.8 pts
60.8% in Q3 2025
History
15 quarters
Since Q1 2023
Sources
15
Documents cited below

Where the Q3 2026 figure comes from

“|| WW | 624 | 459 | 36.1 | 36.0 | 0.1”

Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSPRAVATO (esketamine) — Worldwide operational (constant-currency) growth YoY (%) (%)Year on yearSource
Q3 2026Sep 30, 202636.0%-24.8 ptsForm 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Q2 2026Jun 28, 202640.0%-13.0 ptsForm 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗
Q1 2026Mar 29, 202644.5%+1.6 ptsForm 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗
Q4 2025Dec 28, 202567.8%+22.5 ptsForm 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Q3 2025Sep 28, 202560.8%+5.5 ptsForm 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗
Q2 2025Jun 29, 202553.0%-7.8 ptsForm 8-K (a2025q2exhibit991.htm, filed 2025-07-16) ↗
Q1 2025Mar 30, 202542.9%-29.1 ptsForm 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗
Q4 2024Dec 29, 202445.3%-28.3 ptsForm 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
Q3 2024Sep 29, 202455.3%-25.7 ptsForm 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗
Q2 2024Jun 30, 202460.8%-37.7 ptsForm 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗
Q1 2024Mar 31, 202472.0%-16.0 ptsForm 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗
Q4 2023Dec 31, 202373.6%–Form 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗
Q3 2023Oct 1, 202381.0%–Form 8-K (a2023q3exhibit991.htm, filed 2023-10-17) ↗
Q2 2023Jul 2, 202398.5%–Form 8-K (a2023q2exhibit991.htm, filed 2023-07-20) ↗
Q1 2023Apr 2, 202388.0%–Form 8-K (a2023q1exhibit991.htm, filed 2023-04-18) ↗

Breakdown

What makes up SPRAVATO (esketamine)

Cite this data

StockData. (2026). Johnson & Johnson SPRAVATO (esketamine) (%), quarterly Q1 2023–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-spravato-ops-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.

See a number that looks wrong?